Valuation: Protalix BioTherapeutics, Inc.

Market Cap 179M 154M 145M 132M 248M 17.1B 252M 1.7B 665M 8.57B 672M 657M 28.46B P/E 2026 *
11.7x
P/E 2027 * 18.5x
Enterprise Value 179M 154M 145M 132M 248M 17.1B 252M 1.7B 665M 8.57B 672M 657M 28.46B EV / Sales 2026 *
2.24x
EV / Sales 2027 * 2.62x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-5.93%
1 week-9.76%
Current month-6.33%
1 month-4.72%
3 months+12.12%
6 months-25.25%
Current year+23.33%
1 week 2.17
Extreme 2.17
2.7
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.46
Extreme 1.465
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap.
19/12/25 Buy

Chief Executive Officer

56,000 0.0696%
18/11/25 Sell

Director

168 0.0002%
03/09/25 Free

Chief Operating Officer

75,000 0.0941%
Change 5-day change 1-year change 3-year change Capi.($)
-5.93%-9.76%+50.00%+11.00% 179M
-2.25%-0.47%+68.30%+115.90% 1,052B
-0.66%+0.43%+47.39%+50.54% 627B
-0.54%+1.39%+20.69%+63.99% 441B
-1.99%-3.32%+38.71%+35.41% 349B
-1.05%-2.81%+23.07%+35.70% 287B
-2.12%-3.67%-1.14%+5.37% 241B
-0.63%+1.04%+40.05%+56.09% 224B
-1.19%-3.41%-9.57%-52.71% 202B
+0.16%+3.87%+16.89%+73.73% 172B
Average -1.62%+0.06%+29.44%+39.50% 359.54B
Weighted average by Cap. -1.36%+0.31%+39.09%+61.29%

Financials

2026 *2027 *
Net sales 79.8M 68.92M 64.76M 58.9M 111M 7.63B 113M 759M 297M 3.82B 300M 293M 12.7B 68.19M 58.9M 55.35M 50.34M 94.63M 6.52B 96.2M 649M 254M 3.27B 256M 250M 10.85B
Net income 15.38M 13.28M 12.48M 11.35M 21.34M 1.47B 21.69M 146M 57.17M 736M 57.73M 56.47M 2.45B 10.01M 8.65M 8.13M 7.39M 13.9M 957M 14.12M 95.22M 37.23M 479M 37.59M 36.78M 1.59B
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
14/08/26 $2.220 -5.93% 995,919
13/08/26 $2.360 -9.92% 2,001,846
12/08/26 $2.620 +7.82% 2,012,469
11/08/26 $2.430 -2.02% 373,852
10/08/26 $2.480 +0.81% 773,425
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.220USD
Average target price
11.00USD
Spread / Average Target
+395.50%

Quarterly revenue - Rate of surprise